Brotchie JM - Search Results

1

The nociceptin/orphanin FQ (NOP) receptor antagonist J-113397 enhances the effects of levodopa in the MPTP-lesioned nonhuman primate model of Parkinson's disease.

Visanji NP, de Bie RM, Johnston TH, McCreary AC, Brotchie JM, Fox SH. Visanji NP, et al. Among authors: brotchie jm. Mov Disord. 2008 Oct 15;23(13):1922-5. doi: 10.1002/mds.22086. Mov Disord. 2008. PMID: 18759357

2

Normethylclozapine potentiates the action of quinpirole in the 6-hydroxydopamine lesioned rat.

Fox S, Brotchie J. Fox S, et al. Eur J Pharmacol. 1996 Apr 22;301(1-3):27-30. doi: 10.1016/0014-2999(96)00100-8. Eur J Pharmacol. 1996. PMID: 8773443

3

New treatments for movement disorders?

Fox SH, Brotchie JM. Fox SH, et al. Among authors: brotchie jm. Trends Pharmacol Sci. 1996 Oct;17(10):339-42. doi: 10.1016/s0165-6147(96)30018-7. Trends Pharmacol Sci. 1996. PMID: 8979766 No abstract available.

4

Behavioral effects of 5-HT2C receptor antagonism in the substantia nigra zona reticulata of the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.

Fox SH, Moser B, Brotchie JM. Fox SH, et al. Among authors: brotchie jm. Exp Neurol. 1998 May;151(1):35-49. doi: 10.1006/exnr.1998.6792. Exp Neurol. 1998. PMID: 9582253

5

Adjuncts to dopamine replacement: a pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease.

Brotchie JM. Brotchie JM. Mov Disord. 1998 Nov;13(6):871-6. doi: 10.1002/mds.870130603. Mov Disord. 1998. PMID: 9827609 Review.

6

Quantitative assessment of dyskinesias in subhuman primates.

Brotchie JM, Fox SH. Brotchie JM, et al. Mov Disord. 1999;14 Suppl 1:40-7. Mov Disord. 1999. PMID: 10493402 Review. No abstract available.

7

The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease.

Henry B, Fox SH, Peggs D, Crossman AR, Brotchie JM. Henry B, et al. Among authors: brotchie jm. Mov Disord. 1999 Sep;14(5):744-53. doi: 10.1002/1531-8257(199909)14:5<744::aid-mds1006>3.0.co;2-7. Mov Disord. 1999. PMID: 10495035

8

5-HT(2C) receptor antagonists enhance the behavioural response to dopamine D(1) receptor agonists in the 6-hydroxydopamine-lesioned rat.

Fox SH, Brotchie JM. Fox SH, et al. Among authors: brotchie jm. Eur J Pharmacol. 2000 Jun 9;398(1):59-64. doi: 10.1016/s0014-2999(00)00238-7. Eur J Pharmacol. 2000. PMID: 10856448

9

Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease.

Nash JE, Fox SH, Henry B, Hill MP, Peggs D, McGuire S, Maneuf Y, Hille C, Brotchie JM, Crossman AR. Nash JE, et al. Among authors: brotchie jm. Exp Neurol. 2000 Sep;165(1):136-42. doi: 10.1006/exnr.2000.7444. Exp Neurol. 2000. PMID: 10964492

10

5-HT2C receptor binding is increased in the substantia nigra pars reticulata in Parkinson's disease.

Fox SH, Brotchie JM. Fox SH, et al. Among authors: brotchie jm. Mov Disord. 2000 Nov;15(6):1064-9. doi: 10.1002/1531-8257(200011)15:6<1064::aid-mds1002>3.0.co;2-c. Mov Disord. 2000. PMID: 11104187

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

213 results

Search Page

Filters